Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive ChairmanSAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced a planned leadership transition in which co-founder and Chief Operating Officer David de Vries will succeed Bill Lis as Chief Executive Officer, effective June 1, 2025. Mr. Lis will become Executive Chairman of the Board of Directors.
